MedTrace Logo

F-18 FDG- PETCT in Staging and Recurrent Colorectal Cancer

NCT03572595 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2018-06-28

No results posted yet for this study

Summary

Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States.

The overall relative 5-year survival is about 50%-60% but is highly dependent on disease stage at the time of diagnosis ranging from approximately 80% to only 3%.

Curative treatment comprises resection of the primary tumour combined with adjuvant chemotherapy in selected patients. In recent years there has been an increasing role for curative intended surgical or ablative intervention in limited metastatic disease, i.e., solitary or few metastases to the liver and/or the lungs. Accurate preoperative staging is of paramount importance for directing the most appropriate therapeutic options, for indicating prognosis and outcome, and to avoid futile operations.

Conditions

  • Colo-rectal Cancer
  • Recurrence

Interventions

DIAGNOSTIC_TEST

F-18 FDG-PET/CT

imaging using Positron Emission Tomography/ Computed Tomography with 18F-fluoro-2-deoxyglucose (18F- FDG PET/CT) in Patients with colorectal cancer either for staging or suspecting recurrence

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Mohammed Mekkay, PHD · Assiut University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2019-07-01
Completion
2020-02-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03572595 on ClinicalTrials.gov